213 related articles for article (PubMed ID: 19878763)
61. ACTH-secreting Crooke cell carcinoma of the pituitary.
Kovács GL; Góth M; Rotondo F; Scheithauer BW; Carlsen E; Saadia A; Hubina E; Kovács L; Szabolcs I; Nagy P; Czirják S; Hanzély Z; Kovács K; Horváth É; Korbonits M
Eur J Clin Invest; 2013 Jan; 43(1):20-6. PubMed ID: 23134557
[TBL] [Abstract][Full Text] [Related]
62. Pituitary adenomas: an overview.
Lake MG; Krook LS; Cruz SV
Am Fam Physician; 2013 Sep; 88(5):319-27. PubMed ID: 24010395
[TBL] [Abstract][Full Text] [Related]
63. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
[TBL] [Abstract][Full Text] [Related]
64. High-risk pituitary adenomas and strategies for predicting response to treatment.
Kontogeorgos G; Thodou E; Osamura RY; Lloyd RV
Hormones (Athens); 2022 Mar; 21(1):1-14. PubMed ID: 35061210
[TBL] [Abstract][Full Text] [Related]
65. [Pituitary atypical adenoma or malignant corticotrophinoma?].
Alves M; Paiva I; Belo F; Rebelo O; Bastos M; Carvalheiro M
Acta Med Port; 2011 Dec; 24 Suppl 3():661-6. PubMed ID: 22856408
[TBL] [Abstract][Full Text] [Related]
66. [Aggressive pituitary tumors and carcinomas: modern classification, advances and prospects in treatment].
Astafyeva LI; Kalinin PL; Kobyakov GL; Trunin YY; Ryzhova MV
Zh Vopr Neirokhir Im N N Burdenko; 2024; 88(3):103-110. PubMed ID: 38881023
[TBL] [Abstract][Full Text] [Related]
67. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.
Saeger W; Lüdecke DK; Buchfelder M; Fahlbusch R; Quabbe HJ; Petersenn S
Eur J Endocrinol; 2007 Feb; 156(2):203-16. PubMed ID: 17287410
[TBL] [Abstract][Full Text] [Related]
68. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
69. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
70. Silent pituitary adenomas.
Mayson SE; Snyder PJ
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):79-87. PubMed ID: 25732644
[TBL] [Abstract][Full Text] [Related]
71. The treatment of prolactin-secreting pituitary adenomas. An update.
Limone P; Molinatti GM
Panminerva Med; 1990; 32(2):56-60. PubMed ID: 2250973
[TBL] [Abstract][Full Text] [Related]
72. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
Kaltsas GA; Mukherjee JJ; Plowman PN; Monson JP; Grossman AB; Besser GM
J Clin Endocrinol Metab; 1998 Dec; 83(12):4233-8. PubMed ID: 9851756
[TBL] [Abstract][Full Text] [Related]
73. Current medical treatment and perspective in gonadotroph tumors.
Even-Zohar N; Greenman Y
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101685. PubMed ID: 35871905
[TBL] [Abstract][Full Text] [Related]
74. 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update.
Syro LV; Rotondo F; Ortiz LD; Kovacs K
Endocr Relat Cancer; 2018 Aug; 25(8):T159-T169. PubMed ID: 29535142
[TBL] [Abstract][Full Text] [Related]
75. Atypical pituitary adenoma with orbital invasion: Case report and review of the literature.
Naguib MM; Mendoza PR; Jariyakosol S; Grossniklaus HE
Surv Ophthalmol; 2017; 62(6):867-874. PubMed ID: 28131872
[TBL] [Abstract][Full Text] [Related]
76. Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
Lasolle H; Raverot G
Presse Med; 2016 Jun; 45(6 Pt 2):e211-6. PubMed ID: 27242211
[TBL] [Abstract][Full Text] [Related]
77. Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review.
Moisi M; Cruz AS; Benkers T; Rostad S; Broyles FB; Yuen K; Mayberg M
Cureus; 2016 Jun; 8(6):e658. PubMed ID: 27489751
[TBL] [Abstract][Full Text] [Related]
78. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
Burman P; Trouillas J; Losa M; McCormack A; Petersenn S; Popovic V; Theodoropoulou M; Raverot G; Dekkers OM;
Eur J Endocrinol; 2022 Oct; 187(4):593-605. PubMed ID: 36018781
[TBL] [Abstract][Full Text] [Related]
79. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Donovan LE; Arnal AV; Wang SH; Odia Y
CNS Oncol; 2016 Oct; 5(4):203-9. PubMed ID: 27615706
[TBL] [Abstract][Full Text] [Related]
80. Aggressive pituitary tumours and pituitary carcinomas.
Raverot G; Ilie MD; Lasolle H; Amodru V; Trouillas J; Castinetti F; Brue T
Nat Rev Endocrinol; 2021 Nov; 17(11):671-684. PubMed ID: 34493834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
